Alzinova AB Logo

Alzinova AB

Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.

ALZ | ST

Overview

Corporate Details

ISIN(s):
SE0007413455
LEI:
549300K3IMVT20EK2S13
Country:
Sweden
Address:
Pepparedsleden 1, 431 83 MÖLNDAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alzinova AB is a clinical-stage biopharmaceutical company specializing in the development of disease-modifying treatments for Alzheimer's disease. The company's research is centered on its proprietary AβCC Peptide™ technology, which enables the development of immunotherapies that specifically target neurotoxic amyloid-beta oligomers, a central cause of the disease. Alzinova's pipeline includes both active immunotherapies (vaccines) and passive immunotherapies (antibodies). Its lead candidate, ALZ-101, is a therapeutic vaccine in clinical development designed to be a highly specific treatment to prevent or slow the progression of Alzheimer's disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Alzinova AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alzinova AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alzinova AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-03 Tord Evert Sigfried Labuda Other Other 1,000,000 260,000.00 SEK
2025-04-03 Tord Evert Sigfried Labuda Other Buy 10,000 18,800.00 SEK
2025-04-02 Tord Evert Sigfried Labuda Other Buy 20,000 40,000.00 SEK
2024-12-16 Erik Kullgren Other Buy 10,000 34,400.00 SEK

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.